Travere Therapeutics price target lowered to $43 from $47 at BofA

BofA lowered the firm’s price target on Travere Therapeutics (TVTX) to $43 from $47 and keeps a Buy rating on the shares after the FDA extended its review of the Filspari FSGS sNDA by three months and set a new target action date of April 13. The PDUFA extension is “a setback,” but the outlook for approval still looks positive, the analyst tells investors.